Health Care·Biotechnology·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.38 | N/A | -100.00% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.38 | N/A | -100.00% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management's tone was defensive, highlighting ongoing challenges without providing specific guidance. There was a lack of clarity on future revenue expectations.
Management did not provide specific details on revenue performance.
The company acknowledged challenges in the current market environment.
The earnings report indicates that Biocryst Pharmaceuticals is facing significant challenges, as evidenced by the missed EPS target. The stock reacted negatively, dropping 15.29%, reflecting investor concerns about the company's current performance and lack of guidance. Without clear future expectations, investors may remain cautious in the near term.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PHOTRONICS INC
Feb 20, 2023